{"id":37302,"date":"2016-04-21T13:27:46","date_gmt":"2016-04-21T13:27:46","guid":{"rendered":"http:\/\/healthmedicinet.com\/news\/abbvie-gets-option-on-early-argenx-cancer-drug-for-40-million\/"},"modified":"2016-04-21T13:27:46","modified_gmt":"2016-04-21T13:27:46","slug":"abbvie-gets-option-on-early-argenx-cancer-drug-for-40-million","status":"publish","type":"post","link":"http:\/\/healthmedicinet.com\/news\/abbvie-gets-option-on-early-argenx-cancer-drug-for-40-million\/","title":{"rendered":"AbbVie gets option on early Argenx cancer drug for $40 million"},"content":{"rendered":"<p class=\"canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm canvas-atom\">(Reuters) \u00e2\u20ac\u201c AbbVie has acquired an option on an early-stage immuno-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow.<\/p>\n<p class=\"canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm canvas-atom\">Dutch-Belgian Argenx will receive $40 million upfront from AbbVie for the exclusive option to license ARGX-115 and near-term preclinical milestones of $20 million, the two companies said on Thursday.<\/p>\n<p class=\"canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm canvas-atom\">Argenx is entitled to additional development, regulatory and commercial payments of up to $625 million, if certain targets are achieved, as well as royalties on eventual sales of the experimental drug, which is in pre-clinical development.<\/p>\n<p class=\"canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm canvas-atom\">Finding ways to modulate the body\u00e2\u20ac\u2122s immune system to fight tumors is one of the hottest areas of cancer research and drugmakers are racing to develop new approaches.<\/p>\n<p class=\"canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm canvas-atom\">ARGX-115 works by targeting a protein called GARP believed to contribute to the immunosuppressive effects of T-cells.<\/p>\n<p class=\"canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm canvas-atom\">(Reporting by Ben Hirschler; editing by David Clarke)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Reuters) \u00e2\u20ac\u201c AbbVie has acquired an option on an early-stage immuno-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow. Dutch-Belgian Argenx will receive $40 million upfront from AbbVie for the exclusive option to license ARGX-115 and near-term [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-37302","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts\/37302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/comments?post=37302"}],"version-history":[{"count":0,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts\/37302\/revisions"}],"wp:attachment":[{"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/media?parent=37302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/categories?post=37302"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/tags?post=37302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}